Find disease awareness content and relevant supporting materials

The IAU’s sixth guideline installment offers a comprehensive framework for managing pediatric urolithiasis. It covers etiology, diagnosis, treatment, and prevention strategies, emphasizing conservative care and long-term follow-up to reduce recurrence.

Background: Primary hyperoxalurias are rare diseases with endogenous overproduction of oxalate, thus leading to hyperoxaluria, hyperoxalemia, urolithiasis, and/or nephrocalcinosis and eventually early kidney failure.

Primary hyperoxaluria (PH1) is a condition caused by a hepatic-based enzyme defect which can lead to renal failure due to oxalate stone disease, obstructive uropathy and nephrocalcinosis. It has been shown that the underlying metabolic defect can be corrected by liver transplantation and in most cases (renal failure having already occurred) is accompanied by a kidney graft.

This case report discusses the importance of assessing compliance with conservative treatment in a patient with primary hyperoxaluria type 1 (PH1) who has the I244T/c.969-3C>G mutation. It highlights the successful long-term management of the disease through early and consistent treatment.

Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract illness in young children and a major cause of hospital admissions globally.

The Phase III E1910 trial showed that adding Blincyto (blinatumomab) to chemotherapy significantly improves overall survival in newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL).

Objectives: The pathogenesis of allergic rhinitis (AR) may involve dysregulation of the autonomic nervous system (ANS). Salivary fluid flow and salivary alpha-amylase (sAA) secretion are able to reflect the activity of...

This article reviews all patients who underwent heart transplantation (HTx) within a single institution (172 patients underwent 179 HTx [167 first-time HTxs, 10 second HTxs, 2 third HTxs]) to describe diagnostic...

Stiripentol, an LDHA-targeted oral commercial medication for Dravet syndrome, was recently reported to significantly reduce Uox in one PHI patient with good kidney function after 10 weeks of treatment.